Table 3.
Demographic and clinical characteristic of patients with colorectal cancer in the training and test data set
| Characteristic | Training data set, n = 121 | p- value | Test data set, n = 51 | p- value | ||
|---|---|---|---|---|---|---|
| Wild-type
group (n = 74) |
Mutated
group (n = 47) |
Wild-type
group (n = 31) |
Mutated
group (n = 20) |
|||
| Age, mean ± SD, years | 63.1 ± 8.7 | 71.1 ± 5.4 | <0.05 | 64.2 ± 9.2 | 70.2 ± 4.7 | 0.007 |
| Sex
(male) (female) |
43 (58.1） | 27 (57.4） | 1.00 | 16 (51.6) | 12 (60.0) | 0.76 |
| 31 (41.9) | 20 (42.6) | 15 (48.4) | 8 (40.0) | |||
| Location (left) (right) |
28 (37.8） | 17 (36.2） | 0.73 | 11 (35.5） | 10 (50.0） | 1.00 |
| 46 (62.2) | 30 (63.8) | 20 (64.5) | 10 (50.0） | |||
| T
stage T1 |
3 (4.1) | 1 (2.1) | 0.66 | 0 (0.0) | 0 (0.0) | 1.00 |
| T2 | 5 (6.8) | 6 (12.8) | 2 (6.5) | 1 (5.0) | ||
| T3 | 23 (31.1) | 15 (31.9) | 7 (22.6) | 10 (50.0) | ||
| T4 | 43 (58.1) | 25 (53.2) | 22 (71.0) | 9 (45.0) | ||
| N
stage N0 |
46 (62.2) | 23 (48.9) | 0.09 | 19 (61.3) | 12 (60.0) | 0.72 |
| N1 | 19 (25.7) | 17 (36.2) | 7 (22.6) | 6 (30.0) | ||
| N2 | 5 (6.8) | 7 (14.9) | 5 (16.1) | 2 (10.0) | ||
| N3 | 4 (5.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| LVI
(negative) (positive) |
52 (70.3） | 31 (66.0） | 0.77 | 17 (54.8） | 12 (60.0） | 0.94 |
| 22 (29.7) | 16 (34.0) | 14 (45.2) | 8 (40.0) | |||
| PNI
(negative) (postive) |
57 (77.0） | 40 (85.1） | 0.39 | 25 (80.6） | 14 (70.0） | 0.59 |
| 17 (23.0) | 7 (14.9) | 6 (19.4) | 6 (30.0) | |||
| Pretreatment CEA level (0～5 ng ml−1 vs ≥5 ng ml−1) | 59 (79.7） | 19 (40.4） | <0.05 | 23 (74.1） | 8 (40.0） | 0.03 |
| 15 (20.3） | 28 (59.6） | 8 (25.9) | 12 (60.0） | |||
CEA, carcinoembryonic antigen.
Note: LVI means ‘Lymphatic Vessel Invasion’; PNI means ‘Peripheral nerve invasion’; Pretreatment CEA level means ‘preoperative carcinoembryonic antigen level’.